Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Care Publish Ahead of Print published online ahead of print December 10, 2007
DOI: 10.2337/dc07-0196
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0196v1
31/3/445    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tershakovec, A. M.
Right arrow Articles by Brenner, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tershakovec, A. M.
Right arrow Articles by Brenner, B. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

The Effect of LDL-cholesterol and Treatment with Losartan on End-stage Renal Disease in the RENAAL Study

Andrew M. Tershakovec, MD1, William F. Keane, MD1, Zhongxin Zhang, PhD1, Paulette A. Lyle, BS1, Gerald B. Appel, MD2, Janet B. McGill, MD3, Hans-Henrik Parving, MD4, Mark E. Cooper, MD, PhD5, Shahnaz Shahinfar, MD1 and Barry M. Brenner, MD6

1Merck & Co., Inc., Upper Gwynedd, PA
2Columbia University, New York, NY
3Washington University, St. Louis, MO
4University Hospital of Copenhagen, Copenhagen, Denmark
5Baker Heart Research Institute, Melbourne, Australia
6Renal Division, Brigham and Women's Hospital, Boston, MA

andrew_tershakovec{at}merck.com

ABSTRACT

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between low-density lipoprotein cholesterol (LDL-C) levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at Year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL-C lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.